- Gear Up (Helmets Included) for a Safe Bike Season
- It’s National Nutrition Month: Here’s Tips to Eating Right
- COVID Origins Tied to Raccoon Dogs Sold at Wuhan Market
- Tick-Borne Illness Babesiosis Spreads to New U.S. States
- AHA News: These Healthy Habits Might Also Lead to a Happier Life
- Pets in the Bedroom? Your Sleep Might Suffer, Study Finds
- Chlamydia: What It Is, Symptoms, Treatment & More
- In Mouse Study, Scientists Use Gene Editing to Reverse a Major Cause of Blindness
- Sanofi Follows Lilly, Novo Nordisk in Cutting Insulin Prices
- How Metal Implants Could Mess Up Your Skin
Orbactiv Approved for Drug-Resistant Skin Infections

The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.
The drug is sanctioned to treat methicillin-resistant Staphylococcus aureus (MRSA) and other acute bacterial skin infections. It’s the third such drug approved in 2014, following May approval of Dalvance (dalbavancin) and June approval of Sivextro (tedizolid), the FDA said.
Orbactiv’s safety and effectiveness were evaluated in two clinical studies involving almost 2,000 adults. The most common side effects included headache, nausea, vomiting, skin abscesses on the arms and legs, and diarrhea.
The drug’s label will include a boxed warning that it could interact with the blood-thinning medication warfarin, the agency said.
Orbactiv is marketed by The Medicines Company, based in Parsippany, N.J.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.